CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
Multiple myeloma (MM), characterized by abnormal proliferation of clonal plasma cells, is an incurable hematological malignancy. Various immunotherapy strategies have emerged as an efficacious approach for the treatment of MM, including monoclonal antibodies, antibody-drug conjugates, bispecific an...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2024-10-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://www.mjhid.org/mjhid/article/view/5824 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549756566503424 |
|---|---|
| author | Ugo Testa Elvira Pelosi Germana Castelli |
| author_facet | Ugo Testa Elvira Pelosi Germana Castelli |
| author_sort | Ugo Testa |
| collection | DOAJ |
| description |
Multiple myeloma (MM), characterized by abnormal proliferation of clonal plasma cells, is an incurable hematological malignancy. Various immunotherapy strategies have emerged as an efficacious approach for the treatment of MM, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T (CAR-T) cells. Anti-B-cell maturation antigen (BCMA) CAR-T cells have revolutionized the treatment of MM patients with relapsed/refractory disease and their clinical use was approved for the treatment of these patients.
Despite this progress, the efficacy of CAR-T cells in MM is limited by the responsiveness of only a part of the treated patients, the relapse of other patients, the cost of the treatment and the diminished response in patients with prior exposure to anti-BCMA targeting agents. Ongoing clinical trials are evaluating the use of CAR-T cells at an earlier stage of MM disease and the use of CAR-T cells targeting other membrane antigens expressed on malignant plasma cells.
|
| format | Article |
| id | doaj-art-dc319dc577a34aa4bf295fb24119c0dc |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-dc319dc577a34aa4bf295fb24119c0dc2025-02-03T06:10:04ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062024-10-0116110.4084/MJHID.2024.077CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMAUgo Testa0Elvira Pelosi1Germana Castelli2ISSIstituto Superiore Sanità, Roma.Istituto Superiore Sanità, Roma. Multiple myeloma (MM), characterized by abnormal proliferation of clonal plasma cells, is an incurable hematological malignancy. Various immunotherapy strategies have emerged as an efficacious approach for the treatment of MM, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T (CAR-T) cells. Anti-B-cell maturation antigen (BCMA) CAR-T cells have revolutionized the treatment of MM patients with relapsed/refractory disease and their clinical use was approved for the treatment of these patients. Despite this progress, the efficacy of CAR-T cells in MM is limited by the responsiveness of only a part of the treated patients, the relapse of other patients, the cost of the treatment and the diminished response in patients with prior exposure to anti-BCMA targeting agents. Ongoing clinical trials are evaluating the use of CAR-T cells at an earlier stage of MM disease and the use of CAR-T cells targeting other membrane antigens expressed on malignant plasma cells. https://www.mjhid.org/mjhid/article/view/5824MyelomaCAR T Cells |
| spellingShingle | Ugo Testa Elvira Pelosi Germana Castelli CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA Mediterranean Journal of Hematology and Infectious Diseases Myeloma CAR T Cells |
| title | CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| title_full | CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| title_fullStr | CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| title_full_unstemmed | CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| title_short | CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| title_sort | chimeric antigen receptor t cells for the treatment of multiple myeloma |
| topic | Myeloma CAR T Cells |
| url | https://www.mjhid.org/mjhid/article/view/5824 |
| work_keys_str_mv | AT ugotesta chimericantigenreceptortcellsforthetreatmentofmultiplemyeloma AT elvirapelosi chimericantigenreceptortcellsforthetreatmentofmultiplemyeloma AT germanacastelli chimericantigenreceptortcellsforthetreatmentofmultiplemyeloma |